Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(16min)CommentsSummaryDefinium Therapeutics, Inc. is maintained at a Strong Buy due to imminent 2026 catalysts and robust late-stage pipeline progress.DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD.DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation.With $411.6M cash and no near-term funding needs, DFTX is well-positioned to execute through multiple clinical milestones into 2028.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Kintarapong/iStock via Getty Images The last time I spoke about Definium Therapeutics, Inc. (DFTX) it was with a Seeking Alpha article entitled "Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate." In that article, I mentioned two specific programs thatThis article was written byTerry Chrisomalis14.84K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.